EGFR and familial pancreatic carcinoma: Pancreatic cancers overexpress epidermal growth factor (EGFR), and the presence of this receptor has been shown to correlate with negative outcomes.[6–10] After ligand activation, members of the EGFR family dimerize, trans-autophosphorylate each other, and subsequently activate a wide variety of downstream signals controlling cell proliferation, resistance to apoptosis, invasion, angiogenesis and metastasis.[11] Erlotinib is an orally administered human EGFR tyrosine kinase inhibitor which prevents autophosphorylation of the receptor dimer and activation of downstream targets.